Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
The Canadian Journal of Cardiology|February 18, 2006
Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromesAndrew T Yan, Raymond T Yan, Mary Tan, et al.
European Heart Journal|December 22, 2012
Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpointJeffrey A Bakal, Cynthia M Westerhout, Warren J Cantor, et al.
Diabetes, Obesity & Metabolism|March 3, 2020
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?Ruth L Coleman, Alastair M Gray, Uli C Broedl Md, et al.
Cardiovascular Diabetology|November 27, 2020
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trialJoão Pedro Ferreira, Subodh Verma, David Fitchett, et al.
The Canadian Journal of Cardiology|October 4, 2011
Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus ConferenceG B John Mancini, Steven Baker, Jean Bergeron, et al.
Age and Ageing|October 4, 2019
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trialPedro Monteiro, Richard M Bergenstal, Elvira Toural, et al.
ESC Heart Failure|December 29, 2023
Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular diseaseAbhinav Sharma, Silvio E Inzucchi, Jeffrey M Testani, et al.
American Journal of Preventive Cardiology|June 29, 2023
Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteriaSubodh Verma, Andrew Kosmopoulos, Deepak L Bhatt, et al.
JACC. Heart Failure|August 13, 2018
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes MellitusAbhinav Sharma, Lauren B Cooper, Mona Fiuzat, et al.
The Lancet. Diabetes & Endocrinology|April 26, 2020
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trialsOlivia R Ghosh-Swaby, Shaun G Goodman, Lawrence A Leiter, et al.
Pageof 10